A Cross-Sectional Study of the Phenotypes of Obesity and Insulin Resistance in Adults with Down Syndrome

Diego Real de Asua, Pedro Parra, Ramón Costa, Fernando Moldenhauer, Carmen Suarez

Adult Down Syndrome Outpatient Clinic, Department of Internal Medicine, Fundación de Investigación Biomédica, Hospital Universitario de La Princesa, Madrid, Spain

Background: Despite the confluence of multiple cardiovascular risk factors, subclinical atherosclerotic damage and cardiovascular events remain extremely rare in adults with Down syndrome (DS). We aim to determine the prevalence of obesity and metabolic disorders in an adult cohort with DS and to compare our findings with adults without DS.

Methods: Cross-sectional study of 51 consecutively selected adults with DS living in the community and 51 healthy controls in an outpatient clinic of a tertiary care hospital in Madrid, Spain. Epidemiological data (age and gender), anthropometric data (body mass index and waist-to-height ratio), coexisting clinical conditions, and laboratory data (fasting glucose, insulin, glycated hemoglobin, creatinine, thyroid hormones, vitamins, and lipid profile) were measured and compared between the groups.

Results: Adults with DS were significantly younger and more often men with a higher prevalence of overweight and obesity than controls. Their waist-to-height ratio was higher, and they more frequently had abdominal obesity. The results of an analysis adjusted for age and gender revealed no differences in fasting insulin levels, homeostatic model assessment indexes, or lipid profile between adults with DS and controls.

Conclusion: Adults with DS presented a high prevalence of overweight and obesity. However, we found no differences in lipid profile, prevalence of insulin resistance, or metabolic syndrome between adults with DS and controls.

Keywords: Down syndrome; Hypothyroidism; Insulin resistance; Metabolic syndrome; Obesity, abdominal

INTRODUCTION

Atherosclerosis is the main pathophysiological substrate of cardiovascular disease (CVD), which is the leading cause of morbidity and mortality in Western countries [1]. The prevalence of CVD increases not only with age but also with the presence of multiple concomitant risk factors, such as arterial hypertension, diabetes mellitus, dyslipidemia, obesity, and sedentary lifestyle [2]. When present together, high blood pressure and metabolic risk factors interact to produce the metabolic syndrome, which leads to a greater total CVD risk than the sum of its individual components [3]. Obesity and insulin resistance play a central role in the pathogenesis of metabolic syndrome [4]. The prevalence of obesity is high in all age groups and continues to rise in most Western countries. Of particular concern is the rising prevalence of weight-related disorders in children and adolescents, which can increase their risk of CVD in later life [5,6]. The economic burden of CVD, including healthcare and nonhealthcare-related costs, is increasing in most developed countries, thus highlighting the importance of these diseases in our milieu [7].

Since the 1980s, the improved survival of children with Down syndrome (DS) has resulted in dramatically improved life expectancy for a growing population of adults [8]. A population-based study in the United States revealed an increase in median age at death of adults with DS from 25 years in 1983 to 49 years...
in 1997 [9]. This “new” population of adults with DS raises unique clinical issues, which differ from those of the pediatric population with DS or the general population [10]. Obesity and dyslipidemia appear to be more prevalent in both children and adults with DS [11-13]. Murdoch et al. [14] found no significant differences in mean total cholesterol and triglyceride levels between adults with and without DS; however, other studies have observed a more atherogenic lipid profile in individuals with DS than in the general population [11,13]. Furthermore, a higher incidence of type 1 diabetes mellitus has also been observed in individuals with DS [15].

Despite the confluence of multiple risk factors for CVD, subclinical atherosclerotic damage, and cardiovascular events remain extremely rare in adults with DS [16-18]. In 1977, DS was reported to be an “atheroma-free model”; atheroma was completely absent at autopsy in five institutionalized adults with DS, while atheroma was present in institutionalized adults without DS [14]. Subsequent studies both supported [16] and contradicted this finding [19-21]. Based on carotid intima-media thickness or pulse wave velocity, recent studies found no increase in subclinical vascular damage in adults with DS compared to healthy controls, even though both groups had a similarly elevated risk of CVD [17,18]. However, most previous studies were cross-sectional evaluations of single CVD risk factors in small samples and insufficiently powered to generate any hypothesis for this relevant clinical discrepancy, which could have implications for protection from atherosclerosis in the general population. We present a cross-sectional study with a comprehensive assessment of multiple CVD risk factors, focusing on carbohydrate metabolism, lipids, and adiposity in a cohort of adults with DS. Our working hypothesis was that adults with DS would have a higher prevalence of obesity and subsequent metabolic disorders than adults without DS. Our objectives were to study the prevalence of weight-related and metabolic disorders (states of glycemic dysregulation such as impaired fasting glucose, diabetes mellitus, dyslipidemia, and metabolic syndrome) in adults with DS and to describe any differences with a cohort of healthy controls.

METHODS

Study design

Ours was a cross-sectional study of 51 adults with DS and 51 control participants. The former were consecutively selected from all patients at the Adult Down Syndrome Outpatient Clin-
dex is superior to waist circumference for the diagnosis of abdominal obesity in the general population and is presumed to more truly reflect fat distribution in individuals with a short stature [24].

**Clinical variables**

Clinical variables were obtained through systematic review of medical records, as follows: family history of early CVD events, presence of arterial hypertension, dyslipidemia, diabetes mellitus, smoking, other coexisting conditions (thyroid disorders, obstructive sleep apnea, Alzheimer’s disease), relevant medications (including antihypertensive agents, lipid-lowering agents, antidiabetic drugs, anxiolytics, antidepressants, antipsychotics, antiepileptics, nonsteroidal anti-inflammatory drugs, levothyroxine, glucocorticoids, vitamin B or D supplements, and oral contraceptives/estrogen replacement therapy), office blood pressure, resting heart rate, and fat/fruit/fiber intake. Blood pressure was determined using a validated oscillometric device (OMRON M-6 comfort or OMRON 711 models; OMRON Healthcare, Vernon Hills, IL, USA). Office blood pressure was taken with the participant seated after a minimum 3- to 5-minute rest. Three consecutive measurements were made, with a 1- to 2-minute interval between them, and their mean was considered the final office blood pressure, in accordance with the European Society of Hypertension guidelines [25]. Fat/fruit/fiber consumption was assessed using Block screening questionnaires [26].

**Blood testing**

All participants underwent a fasting blood test after a minimum 10-hour overnight fast. Fasting glucose, fasting insulin, glycated hemoglobin, creatinine, thyroid hormones (thyroid stimulating hormone [TSH] and free thyroxine [FT4]), vitamins (25-OH-vitamin D, vitamin B12, and folic acid), total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol, and triglyceride levels were determined in a Roche/Hitachi modular-D analyzer (Roche Diagnostics GmbH, Mannheim, Germany). Homeostatic model assessment-insulin resistance (HOMA-IR) values were estimated as follows: \[ \frac{\text{glucose (mg/dL) \times insulin (mcU/mL)}}{405} \]. HOMA-β cell function (HOMA-β) values were calculated as follows: \( \frac{360 \times \text{insulin (mcU/mL)}}{\text{glucose (mg/dL)} - 63} \) [27]. We used a HOMA-IR cutoff value of 3.8 (90th percentile), owing to its high specificity for the diagnosis of IR [28]. The definitions used for diagnosis of impaired fasting glucose or diabetes mellitus are as follows:

- Impaired fasting glucose: glucose ≥100 mg/dL and <126 mg/dL
- Diabetes mellitus: glucose ≥126 mg/dL

**Table 1. Anthropometric and clinical characteristics of the study sample**

| Clinical characteristic | Total (n=102) | Down (n=51) | Control (n=51) | P value |
|-------------------------|--------------|------------|----------------|--------|
| Age, yr                 | 39.2±12      | 36±11      | 42.5±12.5      | <0.01  |
| Male gender (%)         | 51 (50)      | 31 (61)    | 20 (39)        | <0.05  |
| Weight, kg              | 68.0±12.2    | 65.9±11.2  | 70.0±13.0      | NS     |
| Height, cm              | 159±12.6     | 151±8      | 167±10         | <0.001 |
| BMI, kg/m²              | 27.0±4.9     | 29.1±5.0   | 24.9±3.8       | <0.001 |
| Normal weight           | 44 (43.1)    | 13 (25.5)  | 31 (61)        | <0.001 |
| Overweight              | 32 (31.4)    | 19 (37)    | 13 (25.5)      |         |
| Obese                   | 26 (25.5)    | 19 (37)    | 7 (14)         |         |
| Waist perimeter, cm     | 91.7±12.2    | 93.5±12.1  | 90.0±12.2      | NS     |
| Abdominal obesity       | 35 (34.3)    | 18 (35)    | 17 (33)        |         |
| WHr                     | 0.58±0.09    | 0.62±0.09  | 0.54±0.08      | <0.001 |
| Pathologic WHr          | 79 (77.4)    | 44 (86)    | 35 (68)        | <0.05  |
| SBP, mm Hg              | 119±14       | 113±13     | 125±13         | <0.001 |
| DBP, mm Hg              | 74±10        | 70±9       | 77±10          | <0.001 |
| Resting heart rate, bpm | 72±10        | 71±11      | 93±10          | <0.001 |
| Hypertension            | 6 (5.8)      | 0          | 6 (12)         | <0.01  |
| Dyslipidemia            | 28 (27.5)    | 17 (33)    | 11 (22)        | NS     |
| T2DM                    | 2 (1.9)      | 2 (3.9)    | 0              | NS     |
| Smoking                 |              |            |                |        |
| Current smoker          | 7 (6.9)      | 0          | 7 (14)         | <0.001 |
| Former smoker           | 8 (7.8)      | 0          | 8 (16)         |         |
| Non-smoker              | 87 (85.3)    | 51 (100)   | 36 (71)        |         |
| Metabolic syndrome      | 13 (12.7)    | 5 (10)     | 8 (17)         | NS     |
| Hypothyroidism          | 42 (41)      | 34 (66)    | 8 (17)         | <0.001 |
| Diet                    |              |            |                |        |
| >30% daily dietary fat  | 79 (77.4)    | 41 (80)    | 38 (74.5)      | NS     |
| Fruit/vegetables portions, n/day | 3.8±1.2 | 4±1 | 3.5 ± 1 | <0.05 |
| <3 daily portions       | 19 (18.6)    | 5 (10)     | 14 (28)        | <0.05  |
| ≥3–4 daily portions     | 45 (44.1)    | 24 (47)    | 21 (41)        |         |
| ≥5 daily portions       | 32 (31.4)    | 20 (39)    | 12 (23.5)      |         |
| Not available           | 6 (5.9)      | 2 (4)      | 4 (8)          |         |
| Dietary fiber intake, g/day | 18±4        | 20±4.5     | 17±3           | <0.001 |

Values are presented as mean ± standard deviation or number (%). NS, not significant; BMI, body mass index; WHr, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, type 2 diabetes mellitus.
Obesity and insulin resistance in Down syndrome

tes mellitus were those of the most recent American Diabetes Association criteria [29]. Dyslipidemia and metabolic syndrome were defined according to modified National Cholesterol Education Program-Adult Treatment Panel III criteria [4].

Statistical analysis
All data were processed using SPSS version 20.0 (IBM Co., Armonk, NY, USA). We compared the prevalence of obesity and overweight, impaired fasting glucose, diabetes, dyslipidemia, and metabolic syndrome between adults with DS and controls, as well as the distribution of the values for blood sugar, adiposity (weight, BMI, waist circumference, and total body fat percentage), and lipids. Qualitative results are presented as absolute frequencies (percentages), whereas quantitative results are presented as means±standard deviations. A chi-square test (with Yates correction when applicable) was used to evaluate statistical significance in the comparison of categorical variables. All analyses were adjusted for age and gender. A multiple logistic regression analysis with all significant variables from the univariate comparison between groups (which included age, gender, BMI, waist-to-height ratio, abdominal fat percentage, TSH levels, and daily fruit and fiber intake), was performed in order to identify possible determinants of IR in adults with DS.

RESULTS
The study population comprised 102 participants (51 adults with DS and 51 controls). All participants were included in the analysis of clinical and anthropometric variables. Three adults with DS and 18 controls refused to provide a blood sample. Therefore, the laboratory results correspond to 48 adults with DS and 33 controls.

Table 2. Description of laboratory parameters in the study sample

| Parameter                        | Total (n=81) | Down (n=48) | Control (n=33) | P value |
|----------------------------------|--------------|-------------|----------------|---------|
| Fasting glucose, mg/dL           | 94±8         | 95±8        | 93±8           | NS      |
| Impaired fasting glucose         | 15 (14.7)    | 10 (19.6)   | 5 (9.8)        | NS      |
| Fasting insulin, mcU/mL          | 12.3±9.1     | 14.1±10.7   | 9.2±3.8        | <0.05   |
| HbA1c, %                         | 5.3±0.3      | 5.3±0.3     | 5.3±0.3        | NS      |
| HOMA-IR                          | 2.94±2.31    | 3.4±2.7     | 2.2±1.0        | <0.05   |
| Insulin resistance               | 13 (12.7)    | 11 (25.6)   | 2 (3.9)        | <0.05   |
| HOMA-β                           | 136±90.5     | 157±107     | 101±34         | <0.01   |
| Creatinine, mg/dL                | 0.9±0.2      | 1.0±0.2     | 0.8±0.1        | <0.001  |
| Total cholesterol, mg/dL         | 202±34       | 201±34      | 204±35         | NS      |
| HDL-C, mg/dL                     | 58±14        | 56±13       | 61±14          | NS      |
| LDL-C, mg/dL                     | 125±31       | 126±31      | 123±30         | NS      |
| Triglycerides, mg/dL             | 101±50       | 103±45      | 98±57          | NS      |
| 25OH-vitamin D                   | 31.6±18.2    | 33.6±20.8   | 27.8±11.4      | NS      |
| TSH, mU/L                        | 3.1±2.3      | 3.4±2.8     | 2.6±1.3        | NS      |

Values are presented as mean±standard deviation or number (%). NS, not significant; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model assessment-insulin resistance index; HOMA-β, homeostasis model assessment-β cell function index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone.

Fig. 1. Distribution of thyroid disorders in the study sample. (A) Prevalence of thyroid disorders in adults with Down syndrome (n=51). (B) Prevalence of thyroid disorders in control subjects (n=51).
Anthropometric differences in adults with DS

The baseline characteristics of the participants are presented in Table 1. Adults with DS were significantly younger (36±11 years vs. 42.5±12.5 years; difference in means –6.5 years; 95% confidence interval [CI], –11.1 to –1.9; P<0.01), more frequently men (31 men with DS [61%] vs. 20 controls [39%]; P<0.05), and showed a higher prevalence of overweight and obesity than controls (normal weight, 13 adults with DS [25.5%] vs. 31 controls [61%]; overweight, 19 adults with DS [37%] vs. 13 controls [25.5%]; obesity, 19 adults with DS [37%] vs. 7 controls [14%]; P<0.001 for the distribution). Adults with DS had a higher waist-to-height ratio (0.62±0.09 vs. 0.54±0.08, difference in means 0.08; 95% CI, 0.05 to 0.11; P<0.001) and were more prevalently classified as having abdominal obesity with this index (44 adults with DS [86%] vs. 35 controls [68%]; P<0.05). These differences remained unchanged after adjusting the analysis for age and gender.

Clinical differences in adults with DS

Coexisting conditions and dietary habits are also listed in Table 1. None of the adults with DS presented arterial hypertension or had ever smoked (P<0.01 for both comparisons with controls). Two adults with DS were newly diagnosed with diabetes mellitus during the study; and a new diagnosis of metabolic syndrome was reached in five adults with DS. Although most participants in both groups presented a high daily fat intake, regular use of olive oil in cooking accounted for most of the excess observed in both groups. Thyroid-related disorders were more frequent in adults with DS, and their distribution in the study groups is depicted in Fig. 1. Out of 34 adults with DS and a prior diagnosis of hypothyroidism, 14 presented subclinical hypothyroidism (average TSH, 6.2±3.3 mU/L), and three more presented iatrogenic subclinical hyperthyroidism at evaluation. Only one participant had low FT4 levels. A prior diagnosis of hypothyroidism was detected in eight controls, of whom three presented subclinical hypothyroidism at the time of the evaluation. Average TSH levels were similar in adults with DS and controls (Table 2).

Regarding the use of medication, adults with DS more often received antidepressants (14 adults with DS vs. 2 controls; P<0.01), neuroleptic drugs (5 adults with DS vs. 0 controls; P<0.05), vitamin D supplements (21 adults with DS vs. 0 controls; P<0.001), and levotyroxine (26 adults with DS vs. 5 controls; P<0.001). All antidepressants were selective serotonin uptake inhibitors, and all were prescribed at doses equivalent to sertraline 100 mg once daily or lower. Antihypertensive agents were more frequently taken by controls (0 adults with DS vs. 6 controls; P<0.05). Statins were taken by six adults with DS and three controls (P=not significant). No other relevant differences in medication were found between the groups.

Evaluation of biochemical parameters of insulin resistance and lipid metabolism

Mean laboratory values are reported in Table 2. Adults with DS had higher fasting insulin levels and a higher prevalence of impaired fasting glucose, although this difference did not reach statistical significance. Both HOMA indexes were also higher in adults with DS, who presented a higher prevalence of insulin resistance than controls, according to HOMA-IR values. However, this statistically significant difference in HOMA indexes did not remain after adjusting the analysis for age and gender (HOMA-IR preadjustment P<0.05, postadjustment P=0.22 [95% CI, –0.5 to 2.2]; and HOMA-β preadjustment P<0.01, postadjustment P=0.1 [95% CI, –9.1 to 95]). A multiple logis-

| Independent variable | OR | Correlation coefficient | Standard error | z  | P value | 95% CI |
|----------------------|----|------------------------|----------------|----|---------|-------|
| Down syndrome        | 0.05 | 0.12 | –1.29 | 0.20 | 0.00–4.54 |
| Age                  | 0.90 | 0.87 | –1.10 | 0.27 | 0.74–1.08 |
| Gender               | 2.36 | 6.71 | 0.30  | 0.76 | 0.01–620.48 |
| BMI                  | 1.52 | 0.59 | 1.09  | 0.27 | 0.72–3.25 |
| WHr                  | 7.14E+11 | 2.11E+13 | 0.92  | 0.36 | 5.08E-14–1.00E+37 |
| TSH                  | 1.10 | 0.22 | 0.45  | 0.65 | 0.74–1.62 |
| Dietary fruit and vegetable portions | 0.57 | 0.50 | –0.63 | 0.53 | 0.10–3.22 |
| Daily fiber intake   | 1.11 | 0.30 | 0.39  | 0.70 | 0.65–1.89 |

OR, odds ratio; CI, confidence interval; BMI, body mass index; WHr, waist-to-height ratio; TSH, thyroid stimulating hormone.
tic regression analysis was performed to identify possible determinants of IR in adults with DS. All variables with a statistically significant difference between groups were selected for the final analysis, which included age, gender, BMI, waist-to-height ratio, abdominal fat percentage, TSH levels, and daily fruit and fiber intake. However, none of the variables presented a significant correlation with the degree of IR in this population (Table 3).

**DISCUSSION**

Abdominal obesity was highly prevalent among adults with DS in our study. Eight out of 10 adults with DS in our sample had a waist-to-height ratio greater than 0.5, and over two-thirds presented overweight or obesity according to their BMI. However, impaired glucose tolerance and insulin resistance were not more frequent among individuals with DS, and no relevant differences in lipid profile were found between the groups.

The proportion of weight-related disorders in our sample is somewhat lower than previously reported. Prasher [12] and Fujiura et al. [30] observed higher rates of obesity among adults with DS (47% of women and 48% of men and 43% of women and 25% of men respectively). Rubin et al. [31] found a higher rate of overweight individuals in this population (56% of women and 45% of men), whereas Melville et al. [11] reported a lower prevalence of obesity. However, direct comparisons with prior series are cumbersome owing to the use of different diagnostic BMI cutoff points. To our knowledge, this is the first report of weight-related disorders in adults with DS living in the community in a Mediterranean setting. In our study, adults with DS ate more daily fruit and vegetables and dietary fiber than controls. Regular use of olive oil in cooking accounted for the excess in dietary fat observed in both groups. These differences could have partially accounted for the lower prevalence of overweight and obesity compared with cohorts in which a Mediterranean diet was not followed [32].

Surprisingly, differences were not observed in insulin resistance parameters or in the lipid profile between groups, even though adults with DS presented higher rates of subclinical hypothyroidism and more regular use of medications which are known to predispose to metabolic disorders, such as selective serotonin uptake inhibitors or neuroleptics [33,34]. These findings contrast with those of prior studies, where lower HDL-C and higher triglyceride levels were consistently documented in children and adults with DS [12,13]. Nevertheless, when fully evaluated, the mean differences in lipid levels observed in those studies, although statistically significant, were not clinically relevant. Furthermore, despite a higher prevalence of abdominal obesity, previous studies were unable to demonstrate a predominance of metabolic syndrome in adults with DS when compared to persons with other types of intellectual disability or healthy controls [35]. Moreover, the role of subclinical hypothyroidism in lipid metabolism when TSH levels are only moderately elevated (as in our cohort) remains open to debate [36]. Since TSH levels were not related to insulin resistance in our multivariate analysis, we believe that these factors did not play a major role in explaining present results. Moreover, other drugs, such as antipsychotics, were prescribed at a low dose. We agree with Adelekan et al. [13] that a possible explanation for these surprising findings could be the peculiar balance between leptin and adiponectin in individuals with DS. Corsi et al. [37] described relative leptin resistance and higher levels of adiponectin in individuals with DS. Surprisingly, Corsi et al. [37] found that leptin levels decreased with age, whereas adiponectin levels were higher in adults and elderly persons with DS. This pathogenic pathway has yet to be explored. The possible effect of a Mediterranean diet in our population could also explain their improved lipid profile [38].

Our study has several strengths. Biological siblings were used as controls, thus reducing the effect of potential genetic and environmental factors. We collected relevant metabolic and anthropometric variables and performed a multivariate analysis to correct our results for possible confounders. Our inclusion criteria were broad, enabling our results to be generalized to most adults with DS. Our study is also subject to a number of limitations. The loss of data related to the refusal to give a blood sample, especially in the control group, left a small sample for laboratory analysis, thus minimizing potential differences in insulin resistance indexes or in the lipid profile. Furthermore, families willing to participate in our study may have siblings with more complex medical needs.

In this study, the prevalence of weight-related disorders (abdominal obesity, overweight, and global obesity) was very high in adults with DS. However, the lipid profile and the prevalence of insulin resistance and metabolic syndrome in this group was very similar to that of controls. The effect of the Mediterranean diet and the role of the leptin-adiponectin pathway warrant further investigation.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

DRA and PP contributed equally to the completion of the study and to drafting the manuscript. DRA, PP, and RC participated in the study design, recruited the participants, reviewed the medical records, and performed the study procedures. DRA and PP performed the statistical analysis and drafted the manuscript. CS and FM conceived the study, helped with its design, and coordinated the recruitment of participants. CS collaborated in the final draft of the manuscript. All authors have read and approved the final version of the manuscript. The authors would like to thank Mr. T. O’Boyle for his kind review of the final draft of the manuscript and Mr. F. Rodriguez for his help with the statistical analysis.

REFERENCES

1. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009.
2. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986;15:254-73.
3. Kassi E, Pervanidou P, Kaltas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48.
4. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009:1-7.
6. Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic syndrome phenotype among U.S. adolescents, 1999-2000. Diabetes Care 2004;27:2438-43.
7. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-9.
8. Irving C, Basu A, Richmond S, Burn J, Wren C. Twenty-year trends in prevalence and survival of Down syndrome. Eur J Hum Genet 2008;16:1336-40.
9. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-25.
10. Kerins G, Petrovic K, Bruder MB, Gruman C. Medical conditions and medication use in adults with Down syndrome: a descriptive analysis. Downs Syndr Res Pract 2008;12:141-7.
11. Melville CA, Cooper SA, McGrother CW, Thorp CF, Collacott R. Obesity in adults with Down syndrome: a case-control study. J Intellect Disabil Res 2005;49(Pt 2):125-33.
12. Prasher VP. Overweight and obesity amongst Down’s syndrome adults. J Intellect Disabil Res 1995;39(Pt 5):437-41.
13. Adelekan T, Magge S, Shults J, Stallings V, Stettler N. Lipid profiles of children with Down syndrome compared with their siblings. Pediatrics 2012;129:e1382-7.
14. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down’s syndrome: an atheroma-free model? Br Med J 1977;2:226-8.
15. Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia 2006;49:1179-82.
16. Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down’s syndrome and atherosclerosis. Atherosclerosis 1989;76:269-72.
17. Draheim CC, Geijer JR, Dengel DR. Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome. Am J Cardiol 2010;106:1512-6.
18. Rodrigues AN, Coelho LC, Goncalves WL, Gouvea SA, Vasconcellos MJ, Cunha RS, Abreu GR. Stiffness of the large arteries in individuals with and without Down syndrome. Vasc Health Risk Manag 2011;7:375-81.
19. Moss TJ, Austin GE. Pre-atherosclerotic lesions in Down syndrome. J Ment Defic Res 1980;24:137-41.
20. Hill DA, Gridley G, Cantrhingius S, Mellemkjaer L, Linet M, Adami HO, Olsen JH, Nyren O, Fraumeni JF Jr. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 2003;163:705-11.
21. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 2005;47:171-6.
22. Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, Mathus-
Obesity and insulin resistance in Down syndrome

Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Zahorska-Markiewicz B; Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008;1:106-16.

23. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 2012;13:275-86.

24. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010;23:247-69.

25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruijgrok W, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamarano JL, Erdine S, Kioussis W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.

26. Block G, Gillespie C, Rosenbaum EH, Jenson C. A rapid food screener to assess fat and fruit and vegetable intake. Am J Prev Med 2000;18:284-8.

27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

28. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmona R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin (Barc) 2001;117:530-3.

29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64-71.

30. Fujiura GT, Fitzsimons N, Marks B, Chicoine B. Predictors of BMI among adults with Down syndrome: the social context of health promotion. Res Dev Disabil 1997;18:261-74.

31. Rubin SS, Rimmer JH, Chicoine B, Braddock D, McGuire DE. Overweight prevalence in persons with Down syndrome. Ment Retard 1998;36:175-81.

32. Bullo M, Garcia-Aloy M, Martinez-Gonzalez MA, Corella D, Fernandez-Ballart JD, Fiol M, Gomez-Gracia E, Estruch R, Ortega-Calvo M, Francisco S, Flores-Mateo G, Serra-Majem L, Pinto X, Covas M, Ros E, Lamuela-Raventos R, Salas-Salvador J. Association between a healthy lifestyle and general obesity and abdominal obesity in an elderly population at high cardiovascular risk. Prev Med 2011;53:155-61.

33. Colotto M, Vinci F, Vo Hong N, Raimo O, Castello A, Carnovale A, Paciaroni A, Coletta P. Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art. Clin Ter 2012;163:e41-5.

34. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 Suppl 1:1-93.

35. Draheim CC, McCubbin JA, Williams DP. Differences in cardiovascular disease risk between nondiabetic adults with mental retardation with and without Down syndrome. Am J Ment Retard 2002;107:201-11.

36. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012;97:326-33.

37. Corsi MM, Dogliotti G, Pedroni F, Galliera E, Malavazos AE, Villa R, Chiappelli M, Licastro F. Adipocytokines in Down’s syndrome, an atheroma-free model: role of adiponectin. Arch Gerontol Geriatr 2009;48:106-9.

38. Estruch R, Ros E, Salas-Salvador J, Covas M, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90.